Aim. To study the safety, lipid-lowering effectiveness, and anti-inflammatory activity of three-month therapy with generic atorvastatin (Atomax) in patients with high cardiovascular risk and dyslipidemia (DLP). Material and methods. The study included 36 DLP patients. Group I (n=17) with coronary heart disease (CND) and normal carbohydrate metabolism, and Group II (n=19) with Type 2 diabetes mellitus (DM-2) and CH D in 52,6% For one month, Atomax was administered in the dose of 10 mg/d, afterwards, the dose was increased up to 20 mg/d if target levels of low-density lipoprotein cholesterol (LDL-CH) were not achieved. Results. The initial Atomax dose resulted in LDL-CH decrease by 33.8% in Group I and by 38,8% in Group II For the mean dose of 14,1 mg/d, the respective percentages were 39,8% and 44,6%, three month later, they reached 23,3-30.3% and 20,6-24,1%, respectively. Increased concentration of high-density lipoprotein CH (HDL-CH) was observed in Group I only (+15,6%). Additionally, Atomax treatment was associated with decreased blood levels of C-reactive protein, tumor necrosis factor-alpha, interleukin 1-beta, and interleukin-6 (the latter decreased in DM-2 patients only). Conclusion. Atomax demonstrated good tolerability, lipid-lowering, and anti-inflammatory effects Increased HDL-CH levels were observed in diabetes-free participants only
